Compounds > bmy 40062
Page last updated: 2024-12-08

bmy 40062

Description

BMY 40062: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID163995
CHEMBL ID98886
SCHEMBL ID9129484
MeSH IDM0168612

Synonyms (10)

Synonym
CHEMBL98886
brn 3656425
1,8-naphthyridine-3-carboxylic acid, 7-(2,5-diazabicyclo(2.2.1)hept-2-yl)-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo-, (1r)-
1,8-naphthyridine-3-carboxylic acid, 1,4-dihydro-7-(2,5-diazabicyclo(2.2.1)hept-2-yl)-1-(1,1-dimethylethyl)-6-fluoro-4-oxo-, (1r)-
bmy 40062
1,8-naphthyridine-3-carboxylic acid, 7-[(1r,4r)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo-
1-tert-butyl-7-[(1r,4r)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
bmy-40062
7-(2,5-diazabicyclo(2.2.1)heptan-2-yl)-1-(1,1-dimethyl)ethyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
SCHEMBL9129484

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" BMY 40062 exhibited longer half-life, higher maximum concentration in serum, greater area under the curve, and better bioavailability in mice after oral dosing than ciprofloxacin."( In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989)		1.44

Dosage Studied

ExcerptRelevanceReference
" BMY 40062 exhibited longer half-life, higher maximum concentration in serum, greater area under the curve, and better bioavailability in mice after oral dosing than ciprofloxacin."( In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.
Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989)		1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (83)

Assay IDTitleYearJournalArticle
AID65380In vitro antibacterial activity against Enterococcus faecalis A98091992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID140680Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg peroral administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID70286Efficacy on systematic infections against Escherichia coli A 15119 after oral administration in mice1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID140679Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg intramuscular administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID68843In vitro minimum inhibitory concentration (MIC) against Escherichia coli A 15119 at 37 degrees C for 18 h.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID23631Plasma half-life after peroral administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID134551Compound was tested for its acute toxicity after peroral(po) administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID205831In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Staphylococcus aureus A 9537.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID134566Dose to protect 50% of mice from lethal infection after intravenous administration1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID222227In vivo efficacy on systemic infections caused by Escherichia coli A15119 in mice after peroral administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID125256In vitro antibacterial activity against Morganella morganii A 151531991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID13549Area under curve measured as conc vs time after intravenous administration to mice.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID23164Half-life time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID27357Acute toxicity after intravenous administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID23630Plasma half-life after intravenous administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID62811Compound was evaluated in vivo in urine sample collected over 24 hours for its concentration after 40 mg/kg peroral administration to dogs.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID206937Compound was tested for the dose to protect 50% of mice from lethal infection against Staphylococcus aureus A 9606 after peroral administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID63901In vitro minimum inhibitory concentration (MIC) against Enterobacter cloacae A 9656 at 37 degrees C for 18 h.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID70591In vitro antibacterial activity against Escherichia coli A 151191991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID27358Acute toxicity after peroral administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID64383In vitro minimum inhibitory concentration (MIC) against Enterococcus faecium A 24885 at 37 degrees C for 18 h.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID210201In vitro antibacterial activity against Streptococcus pneumoniae A 95851991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID64910In vitro antibacterial activity against Escherichia coli A151191992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID23554Solubility (water, 22C, pH 7.2)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID152307In vitro antibacterial activity against Proteus mirabilis A99001992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID222234In vivo efficacy on systemic infections caused by Streptococcus pneumoniae A9585 in mice after peroral administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID164733Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration, MIC) against Pseudomonas aeruginosa A 98431991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID21159Percent urinary recovery in 24 hr after peroral administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID201261In vitro antibacterial activity against Staphylococcus aureus A95371992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID222231In vivo efficacy on systemic infections caused by Staphylococcus aureus A15090 in mice after intramuscular administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID202101In vitro antibacterial activity against Streptococcus pneumoniae A9585.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID205394In vitro antibacterial activity (minimum inhibitory concentration) against Serratia marcescens A 20019.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID222229In vivo efficacy on systemic infections caused by Pseudomonas aeruginosa A9843 in mice after intramuscular administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID68180In vitro antibacterial activity against Enterobacter cloacae A 96561991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID13689Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID10719Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID11145Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID38483In vitro antibacterial activity against Bacteroides fragilis A-22,8621992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID21165percent urinary recovery in 24 hr after intravenous administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID24518Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of peroral administration in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID24516Compound was evaluated in vivo for its half life after 40 mg/kg of peroral administration in dogs.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID222230In vivo efficacy on systemic infections caused by Pseudomonas aeruginosa A9843 in mice after peroral administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID103861In vitro antibacterial activity against Morganella morganii A151531992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID95533In vitro antibacterial activity against Klebsiella pneumoniae A 96641991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID40339Compound was tested in vitro for its antibacterial activity (minimum inhibitory concentration) against Bacteroides fragilis A 22862.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID20933Compound was tested for its solubility at 20 degrees C and isoelectric pH.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID94069Efficacy on systematic infections against Klebsiella pneumoniae A 9664 after oral administration in mice1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID163608Compound was tested for the dose to protect 50% of mice from lethal infection against Pseudomonas aeruginosa A9843 after peroral administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID134569Dose to protect 50% of mice from lethal infection after peroral administration.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID96418In vitro minimum inhibitory concentration (MIC) against Klebsiella pneumoniae A 9664 at 37 degrees C for 18 h1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID11144Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID24186Partition coefficient (logD)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID13900Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID21157Percent of dose administarted, for urinary recovery determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID222226In vivo efficacy on systemic infections caused by Escherichia coli A15119 in mice after intramuscular administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID14289Peak concentration in blood after peroral administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID94297In vitro antibacterial activity against Klebsiella pneumoniae A96641992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID197849Efficacy on systematic infections against Staphylococcus aureus A 9537 after oral administration in mice1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID205830In vitro antibacterial activity against Staphylococcus aureus A 242271991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID67228In vitro antibacterial activity against Enterococcus faecalis A 98091991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID14288Peak concentration in blood after intravenous administration to mice1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID206690Compound was tested for the dose to protect 50% of mice from lethal infection against Streptococcus pneumoniae after peroral administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID222232In vivo efficacy on systemic infections caused by Staphylococcus aureus A15090 in mice after peroral administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID11143Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID13687Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID222233In vivo efficacy on systemic infections caused by Streptococcus pneumoniae A9585 in mice after intramuscular administration1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID64256In vitro minimum inhibitory concentration (MIC) against Enterococcus faecalis A 9808 at 37 degrees C for 18 h.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID162744In vitro antibacterial activity (minimum inhibitory concentration, MIC) against Proteus mirabilis A 99001991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID125278In vitro minimum inhibitory concentration (MIC) against Morganella morganii A 15153 at 37 degrees C for 18 h.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID201746In vitro antibacterial activity against Serratia marcescens A200191992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID150902In vitro minimum inhibitory concentration (MIC) against Pseudomonas aeruginosa A 9843 at 37 degree C for 18 h1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID150907Efficacy on systematic infections against Pseudomonas aeruginosa A 9843 after oral administration in mice1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID13550Area under curve measured as conc vs time after peroral administration to mice.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID134550Compound was tested for its acute toxicity after intravenous (iv) administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID21967Tested for aqueous solubility1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID151545In vitro antibacterial activity against Pseudomonas aeruginosa A98431992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID200257In vitro minimum inhibitory concentration (MIC) against Staphylococcus aureus Smith A 9537 at 37 degrees C for 18 hr1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID24517Compound was evaluated in vivo in blood samples from the orbital sinus for its half life after 40 mg/kg of intramuscular administration in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID198156In vitro minimum inhibitory concentration (MIC) against Serratia marcescens A 20019 at 37 degrees C for 18 hr1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
AID64396In vitro antibacterial activity against Enterobacter cloacae A96561992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-
AID85970In vitro antibacterial activity against Haemophilus influenzae A 215151991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID13691Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
AID70281Compound was tested for the dose to protect 50% of mice from lethal infection against Escherichia coli A 15119 after peroral administration to OF1-strain of female Swiss mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Fluoronaphthyridines and -quinolones as antibacterial agents. 3. Synthesis and structure-activity relationships of new 1-(1,1-dimethyl-2-fluoroethyl), 1-[1-methyl-1-(fluoromethyl)-2-fluoroethyl], and 1-[1,1-(difluoromethyl)-2-fluoroethyl] substituted deri
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		3.0750aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
fenbufen
fenbufen: structure; RN given refers to parent cpd		1.98104-oxo monocarboxylic acid;
biphenyls		non-steroidal anti-inflammatory drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		1.9710difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		1.9710fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.38203-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		1.9810organic heterobicyclic compound;
organonitrogen heterocyclic compound
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		1.9810monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
bicuculline
Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.		1.9810benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		02.3820
Bacterial Infections
Infections by bacteria, general or unspecified.		02.3820
Absence Seizure
[description not available]		01.9810
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9810
chemdatabank.com